|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **NZ Clinical Trials** | **9 November 2024** |  |  |  |  |
| **Name of trial**  | **Outline of trial**  | **Eligible CLL/SCL population**  | **Centres open**  | **Treatment**  | **Website for more information**  |
| **BGB-11417-301 (Celestial)**  | Sonrotoclax +Zanubrutinib vs Venetoclax+Obinutuzimab | Treatment naïve & needing treatment  | Wellington; Christchurch; Tauranga; Auckland City Hospital; North Shore Hospital. **Note:** most available slots have been taken. Each case is being reviewed individually. Some places are available in centres that have recruited low numbers. | A Phase 3, Randomised Study   | <https://clinicaltrials.gov/study/NCT06073821>  |
| **BGB-11417-101**  | BCL2 Inhibitor BGB-11417 (Sonrotoclax); w or wo Zanubrutinib  | Treatment naïve; or relapse/refractory; needing treatment  | Not recruiting at present | A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Sonrotoclax  and Zanubrutinib  | <https://clinicaltrials.gov/study/NCT04277637>   |
| **LOXO-BTK-20030**  | Pirtobritinib versus Ibrutinib | All patients needing treatment   | Dunedin; Waikato | A Phase 3, Randomised Study  |  <https://clinicaltrials.gov/study/NCT05254743> |
| **AbbVie M14-728**  | Venetoclax for Relapsed/refractory CLL/SLL in 17p deletion  | Relapsed/refractory CLL/SLL in 17p deletion  | Christchurch  | Phase 2 trial Participants with 17p deletion status will receive various doses of Venetoclax once daily. | <https://clinicaltrials.gov/study/NCT02966756>  |
| **Bellwave 011**  | Nemtabrutinib Versus Investigator’s Choice of Ibrutinib or Acalabrutinib | Treatment naïve; Needing treatment    | North Shore; Middlemore; Waikato  | A Phase 3, Randomised Study   | [https://clinicaltrials.gov/study/NCT06136559](https://clinicaltrials.gov/study/NCT06136559%C2%A0)  |
| **Rationale**  | Randomised trial of continuing immunoglobulin therapy or stopping with or without prophylactic antibiotics   | Patients with hypogammaglobulinaemia and recurrent infections | Wellington | Phase 3 Clinician ALLG study | [Search for Clinical Trials](https://clinicaltrials.gov/search) |